CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

205552Orig1s000

MICROBIOLOGY REVIEW(S)

MEMORANDUM



DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: 8 July 2013

TO: NDA 205552

FROM: Bryan S. Riley, Ph.D.

Team Leader (Acting)

OPS/New Drug Microbiology Staff

THROUGH: Stephen E. Langille, Ph.D.

Senior Review Microbiologist

OPS/New Drug Microbiology Staff

Diane C. Hanner cc:

Senior Program Management Officer

OND/DHP

SUBJECT: Product Quality Microbiology assessment of Microbial Limits for

Ibrutinib 140 mg Capsules [Submission Date: 28 June 2013]

The Microbial Limits specification for Ibrutinib 140 mg Capsules is acceptable from a Product Quality Microbiology perspective. Therefore, this submission is recommended for approval from the standpoint of product quality microbiology.

Ibrutinib 140 mg Capsules are for oral administration.

The drug product is tested for Microbial Limits at release using a method consistent with USP Chapter <61> (Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests) and <62> (Microbiological Examination of Non-sterile Products: Tests for Specified Microorganisms). The Microbial Limits acceptance criteria are consistent with USP Chapter <1111> (Microbiological Examination of Non-sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use).

Reference ID: 3338318

MEMORANDUM

Table 1 – Microbial Limits Specification

Test	Acceptance Criteria	Method
Total Aerobic Count	NMT (b) (4)	USP <61>
Total Combined Yeast ar	nd NMT	USP <61>
Mold Count		
E. coli	Absent	USP <62>

The Microbial Limits test methods were verified to be appropriate for use with the drug product following procedures consistent with those in USP Chapter <61> and <62>.

The drug product will also be tested for Microbial Limits annually as part of the post-approval stability protocol.

ADEQUATE

Reviewer Comments – The microbiological quality of the drug product is controlled via a suitable testing protocol.

END

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
07/09/2013

STEPHEN E LANGILLE
07/09/2013